Clinical Trials on Pandemic Influenza

Total 2782 results

Visterra, Inc.

Completed

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Influenza A

United States, Australia, Belarus, Belgium, Bulgaria, Canada, Estonia, France, Georgia, Latvia, Malaysia, New Zealand, Russian Federation, Serbia, Singapore, South Africa, Spain, Thailand, Turkey, Ukraine
Vir Biotechnology, Inc.

Completed

Study of VIR-2482 in Healthy Volunteers

Influenza A

Australia
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Influenza A

United States, France, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Israel, India, Thailand, New Zealand, Vietnam, Germany, Latvia, Spain, Russian Federation, Turkey, Argentina, Singapore, Brazil, Hungary, Malaysia, Au... and more
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection

Influenza Prophylaxis

Hungary
Fluart Innovative Vaccine Ltd, Hungary

Completed

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

Human Influenza
University of Warwick

Completed

Influenza 2020/2021

Influenza Vaccine

United Kingdom
The University Clinic of Pulmonary and Allergic...

Completed

Non-specific Response to H1N1 Vaccine

Influenza H1N1

Slovenia
GlaxoSmithKline

Completed

Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

Influenza | Influenza Vaccines

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

Influenza Vaccines

Canada
The University of Texas Health Science Center at...
Sendero Health Plans, Inc.

Unknown

Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019

Influenza, Vaccination

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Human Influenza

Kazakhstan
Green Cross Corporation

Unknown

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

Influenza Vaccine

Korea, Republic of
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010

Seasonal Influenza

Germany
Takeda

Completed

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

Influenza Infection
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011

Seasonal Influenza

Italy
University of Oxford

Completed

A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Vaxart

Completed

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum (ICC H1)

Seasonal Influenza

United States
VaxInnate Corporation
Bill and Melinda Gates Foundation

Completed

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Influenza Infection

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Seasonal Influenza

Colombia, Mexico, Panama, Philippines
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device

Influenza Infection

China
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
University of Pennsylvania
Yale University; Stanford University; Harvard University

Completed

The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates

Seasonal Influenza

United States
Hadassah Medical Organization

Unknown

Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

H1N1 Influenza

Israel
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Centers for Disease Control, Taiwan
Public Health Bureau,Taoyan County Governmnet, Taiwan; Education Department...

Completed

Evaluation of a School-based Influenza Vaccination Program

Influenza | Influenza Vaccines

Taiwan
HaEmek Medical Center, Israel

Completed

The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.

Influenza Vaccines

Israel
Assistance Publique - Hôpitaux de Paris

Terminated

Influenza Vaccination of Nursing Home Workers.

Influenza Disease

France
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Influenza A

China
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Influenza A

China
National Institute of Allergy and Infectious Diseases...

Completed

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates

Reminder Systems | Influenza Vaccines
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Boost in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
Dr. Nechama Sharon

Unknown

Sub Populations of Immune Cells in Influenza A and B Patients

Influenza A and B

Israel
University of Zurich
Schweizerischer Nationalfonds

Completed

Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting (TransFLUas)

Human Influenza

Switzerland
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Adults

Influenza

United States
Beijing Chaoyang District Centre for Disease Control...

Completed

Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

Quadrivalent Influenza Virus Vaccine

China

3

Subscribe